深知“患者在等待”，知名药企携手CSCO，让全球领先的优质患者服务经验在中国复制

“淋巴瘤患者全程管理项目”专家委员会在西安杨森制药有限公司支持下正式成立， 来自全国淋巴瘤领域的27位权威专家获聘。

"Lymphoma Comprehensive Care Project" expert committee sponsored by Xi'an Janssen Pharmaceutical Co., Ltd. was formally established, and 27 top hematologists were selected into the Distinguished experts' panel.

 

本项目由 北京市希思科临床肿瘤学研究基金会（希思科基金会）发起，由中国临床肿瘤学会（CSCO）抗淋巴瘤联盟 负责主要工作，本次专家委员会上制定了 中国首个《中国淋巴瘤患者全程管理规范》 ，并将在全国进行推广和落地。

This project was initiated by the Beijing CSCO Clinical oncology Research Foundation (The CSCO Foundation), and the Chinese Society of Clinical oncology (CSCO) Anti-Lymphoma Alliance is responsible for the implementation. The expert committee reviewed the first "SOPs for the Lymphoma Patient Comprehensive Care" in China, and it will be promoted and implemented nationwide.

 

项目旨在推进实施健康中国2030战略，响应卫健委号召，进一步提高淋巴瘤诊疗能力建设，实现淋巴瘤患者全程的、规范化的管理，推动国内淋巴瘤领域的学科发展，有效提升患者的治疗依从性，切实造福更多淋巴瘤患者。

“随着淋巴瘤领域新的治疗方案、新的治疗理念不断推出，例如以伊布替尼为代表的口服靶向无化疗方案在临床的广泛应用，淋巴瘤患者生存期不断延长，逐渐成为一种慢病，为患者的管理提出了新的课题。”中国临床肿瘤学会(CSCO)监事会监事长马军教授讲到。

中华医学会血液学分会主任委员吴德沛教授表示，我国淋巴瘤患者治疗依从性存在问题，很多患者无法完成规范化、足疗程的治疗，严重影响预期的治疗效果。所以我们应当关注患者在不同疾病阶段和治疗过程中的不同需求，实施患者的全程管理。

 

“淋巴瘤患者的全程管理理念在国外有现成的经验可以借鉴，例如“美国梅奥的患者导航员癌症患者管理模式”和“英国麦克米伦癌症支持”，特别是“患者导航员模式”非常值得借鉴，通过“淋巴瘤全程管理模式”在江苏省人民医院的试点结果来看，通过专员管理患者，患者坚持随访比例达85%，患者的治疗依从性明显提高。”中国临床肿瘤学会(CSCO)抗淋巴瘤联盟副主任委员李建勇教授介绍。

北京市希思科临床肿瘤学研究基金会副理事长、中国临床肿瘤学会(CSCO)理事会副监事长、中国临床肿瘤学会（CSCO）抗淋巴瘤联盟主任委员朱军教授强调，在全程管理的专员、医生和护士三个角色中，专员是当中一个特别重要的环节，成为“医护好帮手、患者好朋友”，可以说起到了一个穿针引线的作用，具有非常重要的地位，我们希望看到通过这个项目，能够催生出一批“患者全程管理示范中心”的医院典型，探索出符合中国国情的创新的患者全程管理模式，进而在全国普及，发扬光大，让全国的淋巴瘤患者都能享受全程管理的服务。

 

在本次大会上，CSCO副秘书长赵东陆教授为专家们梳理了《中国淋巴瘤患者全程管理规范》的框架和主要内容，项目专家组将首先制定针对惰性淋巴瘤患者的管理规范，未来还将推广到其他淋巴瘤亚型，惠及更多患者。

（部分参会专家）

(Part of the experts)

 

“淋巴瘤患者全程管理项目”将通过 “树标准、做培训、审医院、评先进” 四步走，通过集结政府、学会、专家、患者等各方力量，逐步在全国各大医院落地以患者为中心的，“医、护、患”诊疗一体化的患者全程管理模式。

据悉，2017年，西安杨森制药有限公司上市了世界首创的BTK抑制剂伊布替尼，用于治疗慢性淋巴细胞白血病、小淋巴细胞淋巴瘤、套细胞淋巴瘤以及华氏巨球蛋白血症，同期中国初级卫生保健基金会启动了“亿迎新生淋巴瘤患者关爱项目”。

 

“亿迎新生淋巴瘤患者关爱项目”致力于打造服务中国淋巴瘤患者的权威公益平台，该平台是集患者教育、线上咨询、预后筛查、患者管理和随访4大功能为一体的综合性平台，平台成立以来，发布患教内容近千篇，组织患教活动数百场，点击量超10万次，拥有活跃用户超万人，已成为受到广大淋巴瘤患者广泛认可的，在淋巴瘤患者中影响力最大的公益平台之一。

 

药物只是疾病治疗中的一环，如何给患者带来最大获益， 真正做到以“患者为中心”，西安杨森无疑走在了行业的前列， 笔者期待有更多的制药公司能够兑现回馈社会的承诺，努力贡献社会价值，积极融入社区发展，履行企业公民义务，成为能够被社会认可和赞赏的企业。

 

附：“淋巴瘤患者全程管理项目”专家委员会名单 （排名不分先后）

 

 

Top MNC cooperated with CSCO to initiate the world-class cancer support model in China, driven by their belief that patients are waiting.

"Lymphoma Comprehensive Care Project" expert committee sponsored by Xi'an Janssen Pharmaceutical Co., Ltd. was formally established, and 27 top hematologists were selected into the Distinguished experts' panel.

This project was initiated by the Beijing CSCO Clinical oncology Research Foundation (The CSCO Foundation), and the Chinese Society of Clinical oncology (CSCO) Anti-Lymphoma Alliance is responsible for the main work.The expert committee reviewed the first "SOPs for the Lymphoma Patient Comprehensive Care" in China, and it will be promoted and implemented nationwide.

The project aims to promote the implementation of the Healthy China 2030 strategy, and respond to the call of the Health Commission, further improve the capacity building of lymphoma diagnosis and treatment, realize the full-course and standardized management of lymphoma patients, promote the development of the domestic lymphoma field, and effectively improve the treatment compliance of patients, which can effectively benefit more lymphoma patients.

 

"With the continuous introduction of new treatment options and new treatment concepts in the field of lymphoma,such as the more and more usage of oral targeted chemotherapy-free regimens represented by ibrutinib in practice, the survival time of lymphoma patients continues to extend and gradually becomes a kind of chronic disease presents a new topic for the management of patients," said Professor Jun MA, Chairman of the Supervisory Board of the Chinese Society of Clinical oncology (CSCO).

Professor Depei WU, Chairman of Chinese Society of Hematology, said that Chinese  lymphoma patients have poor treatment compliance, and many patients can not complete standard and full course of treatment, which seriously affects the expected treatment effect. Therefore, we should pay attention to the different needs of patients in different disease stages and treatment processes and implement comprehensive care of patients.

"The comprehensive care concept of lymphoma patients can be learned from the existing experience of western countries, such as the "Cancer patient Navigator model of the Mayo clinic the United States" and "Macmillan Cancer Support in the United Kingdom," especially the "patient navigator model." It is worth sharing the "Lymphoma Comprehensive Care Model" pilot results in Jiangsu Provincial Hospital. The navigator supports the patients. As a result, the patient adheres to the follow-up rate as high as 85%, and the patient's treatment compliance is significantly improved. "Professor Jianyong Li, Vice Chairman of the Chinese Society of Clinical oncology (CSCO) Anti-Lymphoma Alliance, introduced.

Professor Jun ZHU, Vice Chairman of Beijing CSCO Clinical oncology Research Foundation, Vice Chairman of Chinese Society of Clinical oncology (CSCO), and Chairman of the Anti-Lymphoma Alliance of the Chinese Society of Clinical oncology (CSCO) mentioned that among the three roles of the navigator, doctor, and nurse in the comprehensive care, the navigator is a critical role, becoming a "good helper of medical staff and a good friend of patients," which played a critical role of the bridge patients and medical care. We hope that through this project, many hospital models of "patient comprehensive care demonstration centers" can be spawned, and innovative patient comprehensive care models that meet China's domestic conditions can be explored and then popularized and carried forward throughout China so that lymphoma patients in China can enjoy comprehensive care services. 

At this meeting, Professor Donglu ZHAO, CSCO Deputy Secretary-General, sorted out the framework and the detailed content of the "SOPs of Lymphoma Patient Comprehensive Care." The expert group of this project will first formulate management practices for indolent lymphoma patients. In the future, it will be extended to other lymphoma subtypes, benefiting more patients.

The implementation plan of the Lymphoma Comprehensive Care Project has four steps: standards setting, training, hospital accreditation, and best case sharing. Through the cooperation of government, academic groups, doctors, and patients, we hope this project will implement the lymphoma patient-centered integrated care model across China.

It is reported that in 2017, Xi'an Janssen Pharmaceutical Co., Ltd. put the world's first BTK inhibitor ibrutinib launched for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. At the same time, the China Primary Health Care Foundation launched the "iFuture Lymphoma Patient Care center."

"iFuture Lymphoma Patient Care center" is committed to building an trusted patient service platform for Chinese lymphoma patients. This platform is a comprehensive platform integrating patient education, online consultation, prognosis screening, patient management, and follow-up. Since the establishment of the platform, it has published nearly a thousand articles on patient education, organized hundreds of events on patient education, with more than 100,000 hits and more than 10,000 active users. It has become one of the public welfare platforms widely recognized by the majority of lymphoma patients and one of the most influential platforms in lymphoma patients.

Drugs are only one part of disease treatment. To bring the most significant benefit to patients and truly "patient-centered," Xi'an Janssen is undoubtedly at the forefront. The author hopes that more pharmaceutical companies will give back to society, strive to contribute social value, actively participate in community development, fulfill corporate citizenship obligations, and become a company that can be recognized and appreciated by society.